









Mercados
/
Ações
/
nasdaq-incy
/

Incyte Corp

INCY

76.487USD

+0.897+1.19%

Horário de mercado （ET）Cotações atrasadas em 15 min

14.85BValor de mercado

698.07P/L TTM



Incyte Corp

76.487

+0.897+1.19%

Visão Geral Empresa Serviços Financeiros

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

Informações da empresa

Código da empresaINCY

Nome da EmpresaIncyte Corp

Data de listagemDec 06, 1993

CEOMr. Bill Meury

Número de funcionários2617

Tipo de títulosOrdinary Share

Fim do ano fiscalDec 06

Endereço1801 Augustine Cut-Off

CidadeWILMINGTON

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal19803

Telefone13024986700

Sitehttps://www.incyte.com/

Código da empresaINCY

Data de listagemDec 06, 1993

CEOMr. Bill Meury

Executivos da empresa

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Herve Hoppenot

Director

1.62M

-3.14%

Mr. Julian C. Baker

Independent Chairman of the Board

278.77K

Ms. Christiana Stamoulis

Executive Vice President, Chief Financial Officer

263.82K

-1.25%

Mr. Paul J. Clancy

Independent Director

146.88K

+2.00%

Mr. Jean-Jacques Bienaime ,

Independent Director

144.77K

+1.77%

Ms. Paula J. Swain

Executive Vice President - Human Resources

106.48K

-0.80%

Mr. Michael James Morrissey

Executive Vice President, Head - Global Technical Operations

86.16K

+5.70%

Dr. Katherine A. High, M.D.

Independent Director

66.08K

+3.96%

Dr. Otis W. Brawley, M.D.

Independent Director

50.10K

+5.29%

Dr. Susanne Schaffert, Ph.D.

Independent Director

37.95K

+4.60%

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Herve Hoppenot

Director

1.62M

-3.14%

Mr. Julian C. Baker

Independent Chairman of the Board

278.77K

Ms. Christiana Stamoulis

Executive Vice President, Chief Financial Officer

263.82K

-1.25%

Mr. Paul J. Clancy

Independent Director

146.88K

+2.00%

Mr. Jean-Jacques Bienaime ,

Independent Director

144.77K

+1.77%

Ms. Paula J. Swain

Executive Vice President - Human Resources

106.48K

-0.80%

Detalhamento da receita

Moeda: USDAtualizado em: dom, 6 de jul

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

JAKAFI revenues

709.41M

67.38%

OPZELURA revenues

118.70M

11.27%

JAKAVI product royalty revenues

92.14M

8.75%

OLUMIANT product royalty revenues

30.80M

2.93%

MINJUVI revenues

29.55M

2.81%

Other

72.28M

6.87%

Sem dados

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

JAKAFI revenues

709.41M

67.38%

OPZELURA revenues

118.70M

11.27%

JAKAVI product royalty revenues

92.14M

8.75%

OLUMIANT product royalty revenues

30.80M

2.93%

MINJUVI revenues

29.55M

2.81%

Other

72.28M

6.87%

Distribuição de ações

Atualizado em: sáb, 19 de jul

Investidores

Tipos de investidores

Investidores

Proporção

Baker Bros. Advisors LP

15.61%

The Vanguard Group, Inc.

10.20%

Dodge & Cox

7.61%

BlackRock Institutional Trust Company, N.A.

6.10%

State Street Global Advisors (US)

5.14%

Other

55.34%

Investidores

Proporção

Baker Bros. Advisors LP

15.61%

The Vanguard Group, Inc.

10.20%

Dodge & Cox

7.61%

BlackRock Institutional Trust Company, N.A.

6.10%

State Street Global Advisors (US)

5.14%

Other

55.34%

Tipos de investidores

Investidores

Proporção

Investment Advisor

37.07%

Investment Advisor/Hedge Fund

35.74%

Hedge Fund

21.03%

Pension Fund

3.11%

Individual Investor

2.16%

Research Firm

1.99%

Bank and Trust

1.17%

Sovereign Wealth Fund

1.00%

Venture Capital

0.22%

Participação acionária institucional

Atualizado em: ter, 1 de jul

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q2

1417

201.03M

102.93%

+1.34M

2025Q1

1457

199.01M

102.81%

-12.15M

2024Q4

1448

191.80M

99.11%

-19.23M

2024Q3

1401

192.85M

100.02%

-35.92M

2024Q2

1385

209.06M

108.78%

-39.98M

2024Q1

1357

227.85M

101.54%

-21.15M

2023Q4

1323

228.89M

102.19%

-14.49M

2023Q3

1300

224.25M

100.13%

-17.63M

2023Q2

1306

220.30M

98.76%

-17.67M

2023Q1

1294

227.74M

102.15%

-615.23K

Ver Mais

Atividade dos acionistas

Nome

Ações detidas

Proporção

Variação

Var. %

Data

Baker Bros. Advisors LP

30.49M

15.75%

+984.00

+0.00%

Jun 30, 2025

The Vanguard Group, Inc.

19.91M

10.29%

+403.13K

+2.07%

Mar 31, 2025

Dodge & Cox

14.86M

7.68%

-55.30K

-0.37%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

11.92M

6.16%

+257.27K

+2.21%

Mar 31, 2025

State Street Global Advisors (US)

10.04M

5.18%

+4.32K

+0.04%

Mar 31, 2025

AQR Capital Management, LLC

6.74M

3.48%

+3.23M

+92.31%

Mar 31, 2025

Geode Capital Management, L.L.C.

4.21M

2.17%

+167.91K

+4.16%

Mar 31, 2025

Renaissance Technologies LLC

3.71M

1.92%

-377.20K

-9.23%

Mar 31, 2025

LSV Asset Management

3.64M

1.88%

+170.48K

+4.92%

Mar 31, 2025

Invesco Capital Management LLC

2.74M

1.42%

+98.11K

+3.71%

Mar 31, 2025

Ver Mais

ETFs Relacionados

Atualizado em: sáb, 2 de ago

Nome

Proporção

iShares Genomics Immunology and Healthcare ETF

4.03%

First Trust NYSE Arca Biotechnology Index Fund

3.76%

Invesco Biotechnology & Genome ETF

2.77%

SPDR S&P Biotech ETF

2.41%

Bushido Capital US Equity ETF

2.11%

VanEck Biotech ETF

2.07%

Strategas Global Policy Opportunities ETF

1.91%

Virtus LifeSci Biotech Products ETF

1.9%

Invesco S&P 500 Equal Weight Health Care ETF

1.64%

ROBO Global Healthcare Technology & Innovation ETF

1.6%

Ver Mais

iShares Genomics Immunology and Healthcare ETF

Proporção4.03%

First Trust NYSE Arca Biotechnology Index Fund

Proporção3.76%

Invesco Biotechnology & Genome ETF

Proporção2.77%

SPDR S&P Biotech ETF

Proporção2.41%

Bushido Capital US Equity ETF

Proporção2.11%

VanEck Biotech ETF

Proporção2.07%

Strategas Global Policy Opportunities ETF

Proporção1.91%

Virtus LifeSci Biotech Products ETF

Proporção1.9%

Invesco S&P 500 Equal Weight Health Care ETF

Proporção1.64%

ROBO Global Healthcare Technology & Innovation ETF

Proporção1.6%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações

Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados

KeyAI

